clotrimazole/betamethasone (Rx)

Brand and Other Names:Lotrisone
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

clotrimazole/betamethasone

cream/lotion

  • 0.05%/1%

Tinea Pedis, Tinea Cruris, & Tinea Corporis

Apply to infected area q12hr for 2 weeks for tinea cruris and tinea corporis; 4 weeks for tinea pedis

Allergic or Inflammatory Diseases

Apply to affected area in the morning and evening

<17 years: Safety and efficacy not established

Next:

Interactions

Interaction Checker

and clotrimazole/betamethasone

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            1-10%

            Dry skin (2%)

            Paresthesia (2%)

            Local burning (2%)

            <1%

            Edema

            Rash

            Skin atrophy

            Secondary infection

            Skin ulceration

            Acneiform eruption

            Bruising

            Folliculitis

            Striae

            Clotrimazole

            Erythema

            Stinging

            Blistering

            Peeling

            Edema

            Pruritus

            Urticaria

            General skin irritation

            Postmarketing reports

            • Blurred vision, cataracts, glaucoma, increased intraocular pressure

            Betamethasone

            Burning

            Itching

            Irritation

            Dryness

            Folliculitis

            Hypertrichosis

            Acneiform eruptions

            Hypopigmentation

            Perioral dermatitis

            Allergic contact dermatitis

            Skin maceration

            Skin atrophy

            Striae

            Miliaria

            HPA suppression (with higher potency used >2 wk)

            Previous
            Next:

            Warnings

            Contraindications

            Documented hypersensitivity

            Cautions

            Do not use with occlusive dressing; systemic absorptioin of topical corticosteroids may cause hypercorticism or suppression of hypothalamic-pituitary-adrenal axis

            Prolonged treatment with corticosteroids associated with development of Kaposi sarcoma

            Topical corticosteroids may be absorbed percutaneously and result in manifestations of Cushing syndrome

            Use of topical corticosteroids may increase risk of posterior subcapsular cataracts and glaucoma; cataracts and glaucoma reported in postmarketing experience with use of topical corticosteroid products, including topical betamethasone products; avoid contact with eyes; advise patients to report any visual symptoms and consider referral to ophthalmologist for evaluation

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            There are no available data on topical betamethasone dipropionate or clotrimazole use in pregnant women to identify drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; observational studies suggest an increased risk of low birthweight infants with use of potent or very potent topical corticosteroid during pregnancy

            Advise pregnant women that therapy may increase risk of having a low birthweight infant and to use drug on the smallest area of skin and for shortest duration possible

            Animal data

            • In an animal reproduction study, betamethasone dipropionate caused malformations (ie, umbilical hernias, cephalocele, and cleft palate) in pregnant rabbits when given by intramuscular route during organogenesis
            • The available data do not allow calculation of relevant comparisons between systemic exposure of clotrimazole and/or betamethasone dipropionate observed in animal studies to systemic exposure that would be expected in humans after topical use of drug

            Lactation

            Advise a woman to apply drug to smallest area of skin and for shortest duration possible while breastfeeding; advise breastfeeding women not to apply drug directly to nipple and areola to avoid direct infant exposure

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Betamethasone: Decreases inflammation by stabilizing leukocyte lysosomal membranes

            Clotrimazole: Binds to phospholipids in fungal cell membrane, which alters cell wall permeability and results in the loss of intracellular elements; fungistatic and fungicidal

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.